The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics
Open accessAbstract
Neurodegenerative disorders are primarily characterized by neuron loss. The most common neurodegenerative disorders include Alzheimer’s and Parkinson’s disease. Although there are several medicines currently approved for managing neurodegenerative disorders, a large majority of them only help with associated symptoms. This lack of pathogenesis-targeting therapies is primarily due to the restrictive effects of the blood–brain barrier (BBB), which keeps close to 99% of all “foreign substances” out of the brain. Since their discovery, nanoparticles have been successfully used for targeted delivery into many organs, including the brain. This review briefly describes the pathophysiology of Alzheimer’s, Parkinson’s disease, and amyotrophic lateral sclerosis, and their current management approaches. We then highlight the major challenges of brain-drug delivery, followed by the role of nanotherapeutics for the diagnosis and treatment of various neurological disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical data have shown that aducanumab can decrease the load of Aβ plaques but does not improve cognitive function in AD patients.424”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [424]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bhargava, K., Arya, A., Gangwar, A., Singh, S. K., Roy, M., Das, M., & Sethy, N. K. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s102096 · Cited by 79
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924 · cited 1×
“The use of melatonin or clonazepam is suggested for sleep-related symptoms [62].”
BackgroundThe blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Network hubs in the human brain
van den Heuvel, M. P., & Sporns, O. (2013) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2013.09.012 · Cited by 2,123 · cited 1×
“Neurons are central to the proper functioning of the human brain since they play a critical role in communication [7,8].”
BackgroundMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Structural Basis of the Drug-binding Specificity of Human Serum Albumin
Ghuman, J., Zunszain, P. A., Petitpas, I., Bhattacharya, A. A., Otagiri, M., & Curry, S. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.075 · Cited by 1,941
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, K. R., & Schapira, A. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,738
Apoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605
MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135718 · Cited by 1,280
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954 · cited 1×
“The efficacy of systematically administered drugs is mostly determined by their pharmacokinetic characteristics [83].”
BackgroundOxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications
Liu, Z., Zhou, T., Ziegler, A. C., Dimitrion, P., & Zuo, L. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2525967 · Cited by 810
Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease
Argaw, A. T., Asp, L., Zhang, J., Navrazhina, K., Pham, T., Mariani, J. N., Mahase, S., Dutta, D. J., Seto, J., Kramer, E. G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60842 · Cited by 733
A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes
Nakagawa, S., Deli, M. A., Kawaguchi, H., Shimizudani, T., Shimono, T., Kittel, Á., Tanaka, K., & Niwa, M. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.002 · Cited by 728
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Zhou, H., S. Beevers, C., & Huang, S. (2011) · Current Drug Targets · doi:10.2174/138945011794815356 · Cited by 715
Klockgether, T., Mariotti, C., & Paulson, H. L. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0074-3 · Cited by 696
Schulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
Lockman, P. R., Mumper, R. J., Khan, M. A., & Allen, D. D. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120001481 · Cited by 592 · cited 1×
“The physicochemical properties of compounds that allow their transport across the BBB include the size, molecular weight, surface activity, lipid solubility, and charge [74,75].”
Backgroundvan de Waterbeemd, H., Camenisch, G., Folkers, G., Chretien, J. R., & Raevsky, O. A. (1998) · Journal of Drug Targeting · doi:10.3109/10611869808997889 · Cited by 587
Series Introduction: Neurodegeneration: What is it and where are we?
Przedborski, S., Vila, M., & Jackson-Lewis, V. R. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17522 · Cited by 584
Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors
Emamzadeh, F. N., & Surguchov, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00612 · Cited by 568
Sengillo, J. D., Winkler, E. A., Walker, C. T., Sullivan, J. S., Johnson, M., & Zlokovic, B. V. (2013) · Brain Pathology · doi:10.1111/bpa.12004 · Cited by 553
ABC Transporters and the Blood-Brain Barrier
Begley, D. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384844 · Cited by 545
Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis
John van Geest Centre for Brain Repair, D. O. C. N., Kouli, A., Torsney, K. M., Department of Medicine for the Elderly, C. U. H. N. F. T., Clinical Gerontology Unit, D. O. P. H. A. P. C., Kuan, W.-L., & John van Geest Centre for Brain Repair, D. O. C. N. (2018) · Parkinson’s Disease: Pathogenesis and Clinical Aspects · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1 · Cited by 507
Mechanism of action of memantine
JOHNSON, J., & KOTERMANSKI, S. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.09.007 · Cited by 502
The role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
Jaiswal, M. K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21528 · Cited by 451
Environmental Risk Factors and Parkinson's Disease: A Metaanalysis
Priyadarshi, A., Khuder, S. A., Schaub, E. A., & Priyadarshi, S. S. (2001) · Environmental Research · doi:10.1006/enrs.2001.4264 · Cited by 446
Interactions of pathological proteins in neurodegenerative diseases
Spires-Jones, T. L., Attems, J., & Thal, D. R. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1709-7 · Cited by 429
Molecular Basis of the Neurodegenerative Disorders
Martin, J. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906243402507 · Cited by 418
Distribution, Translocation and Accumulation of Silver Nanoparticles in Rats
Tang, J., Xiong, L., Wang, S., Wang, J., Liu, L., Li, J., Yuan, F., & Xi, T. (2009) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2009.1269 · Cited by 414
The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy
Webster, C. P., Smith, E. F., Bauer, C. S., Moller, A., Hautbergue, G. M., Ferraiuolo, L., Myszczynska, M. A., Higginbottom, A., Walsh, M. J., Whitworth, A. J., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201694401 · Cited by 404
Anatomy and physiology of the blood-brain barrier
Serlin, Y., Shelef, I., Knyazer, B., & Friedman, A. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.01.002 · Cited by 397
Protein size and cerebrospinal fluid composition
Felgenhauer, K. (1974) · Klinische Wochenschrift · doi:10.1007/bf01466734 · Cited by 396
Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion
Fischer, H., Gottschlich, R., & Seelig, A. (1998) · Journal of Membrane Biology · doi:10.1007/s002329900434 · Cited by 371
Hampel, H., Mesulam, M.-M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.43 · Cited by 369
A Pathologic Cascade Leading to Synaptic Dysfunction in -Synuclein-Induced Neurodegeneration
Scott, D. A., Tabarean, I., Tang, Y., Cartier, A., Masliah, E., & Roy, S. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1091-10.2010 · Cited by 353
Inflammation in central nervous system injury
Allan, S. M., & Rothwell, N. J. (2003) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.2003.1358 · Cited by 345
The role of stress in neurodegenerative diseases and mental disorders.
Esch, T., Stefano, G. B., Fricchione, G. L., & Benson, H. (2002) · PubMed · Cited by 312
Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease
Milnerwood, A. J., & Raymond, L. A. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.08.002 · Cited by 312
Khongkow, M., Yata, T., Boonrungsiman, S., Ruktanonchai, U. R., Graham, D., & Namdee, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-44569-6 · Cited by 303
Early Postnatal Astroglial Cells Produce Multilineage Precursors and Neural Stem Cells In Vivo
Ganat, Y. M., Silbereis, J., Cave, C., Ngu, H., Anderson, G. M., Ohkubo, Y., Ment, L. R., & Vaccarino, F. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2532-06.2006 · Cited by 264
Bayer (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00008 · Cited by 252
Approval of Aducanumab for Alzheimer Disease—The FDA’s Perspective
Dunn, B., Stein, P., & Cavazzoni, P. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.4607 · Cited by 246
Tight junction modulation of the blood brain barrier: CNS delivery of small molecules
Greene, C., & Campbell, M. (2016) · Tissue Barriers · doi:10.1080/21688370.2015.1138017 · Cited by 246
Memantine for the Treatment of Dementia: A Review on its Current and Future Applications
Folch, J., Busquets, O., Ettcheto, M., Sánchez-López, E., Castro-Torres, R. D., Verdaguer, E., Garcia, M. L., Olloquequi, J., Casadesús, G., Beas-Zarate, C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170672 · Cited by 245
Nanotoxicology and Nanosafety: Safety-by-Design and Testing at a Glance
Zielińska, A., Costa, B., Ferreira, M. V., Miguéis, D., Louros, J. M. S., Durazzo, A., Lucarini, M., Eder, P., V. Chaud, M., Morsink, M., et al. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134657 · Cited by 245
Molecular pathology of neurodegenerative diseases: principles and practice
Kovacs, G. G. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205952 · Cited by 242
Multiple risk factors for Parkinson's disease
Gorell, J. M., Peterson, E. L., Rybicki, B. A., & Johnson, C. C. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.09.014 · Cited by 230
Parkinson's disease: The syndrome, the pathogenesis and pathophysiology
Bartels, A. L., & Leenders, K. L. (2009) · Cortex · doi:10.1016/j.cortex.2008.11.010 · Cited by 225
Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers
Poovaiah, N., Davoudi, Z., Peng, H., Schlichtmann, B., Mallapragada, S., Narasimhan, B., & Wang, Q. (2018) · Nanoscale · doi:10.1039/c8nr04073g · Cited by 225
Kim, J.-Y., Choi, W. I., Kim, Y. H., & Tae, G. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.047 · Cited by 219
Hladky, S. B., & Barrand, M. A. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0113-6 · Cited by 206
Sharma, G., Modgil, A., Layek, B., Arora, K., Sun, C., Law, B., & Singh, J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.016 · Cited by 184
Self-citationNanomaterial based drug delivery systems for the treatment of neurodegenerative diseases
Masoudi Asil, S., Ahlawat, J., Guillama Barroso, G., & Narayan, M. (2020) · Biomaterials Science · doi:10.1039/d0bm00809e · Cited by 181
Pickett, E. K., Herrmann, A. G., McQueen, J., Abt, K., Dando, O., Tulloch, J., Jain, P., Dunnett, S., Sohrabi, S., Fjeldstad, M. P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.044 · Cited by 179
Challenges in drug delivery to the brain: Nature is against us
Krol, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.044 · Cited by 176
Butterfield, D. A., Griffin, S., Munch, G., & Pasinetti, G. M. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4309 · Cited by 175
Nanomaterials for Drug Delivery to the Central Nervous System
Teleanu, D. M., Neguț, I., Grumezescu, V., Grumezescu, A. M., & Teleanu, R. I. (2019) · Nanomaterials · doi:10.3390/nano9030371 · Cited by 171
Gonzalez-Carter, D. A., Leo, B. F., Ruenraroengsak, P., Chen, S., Goode, A. E., Theodorou, I. G., Chung, K. F., Carzaniga, R., Shaffer, M. S. P., Dexter, D. T., et al. (2017) · Scientific Reports · doi:10.1038/srep42871 · Cited by 170
Evidence-based approach to assess passive diffusion and carrier-mediated drug transport
Di, L., Artursson, P., Avdeef, A., Ecker, G. F., Faller, B., Fischer, H., Houston, J. B., Kansy, M., Kerns, E. H., Krämer, S. D., et al. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.03.015 · Cited by 167
Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives
Harilal, S., Jose, J., Parambi, D. G. T., Kumar, R., Mathew, G. E., Uddin, M. S., Kim, H., & Mathew, B. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13132 · Cited by 166
Advances in the treatment of neurodegenerative disorders employing nanotechnology
Modi, G., Pillay, V., & Choonara, Y. E. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05108.x · Cited by 164
Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?
de Paula, V. D. J. R., Guimarães, F. M., Diniz, B. S., & Forlenza, O. V. (2009) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642009dn30300003 · Cited by 164
Revisiting FDA Approval of Aducanumab
Alexander, G. C., Knopman, D. S., Emerson, S. S., Ovbiagele, B., Kryscio, R. J., Perlmutter, J. S., & Kesselheim, A. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2110468 · Cited by 162
Balducci, C., Mancini, S., Minniti, S., La Vitola, P., Zotti, M., Sancini, G., Mauri, M., Cagnotto, A., Colombo, L., Fiordaliso, F., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0284-14.2014 · Cited by 162
Locatelli, E., Naddaka, M., Uboldi, C., Loudos, G., Fragogeorgi, E., Molinari, V., Pucci, A., Tsotakos, T., Psimadas, D., Ponti, J., et al. (2014) · Nanomedicine · doi:10.2217/nnm.14.1 · Cited by 159
Bhatt, R., Singh, D., Prakash, A., & Mishra, N. (2015) · Drug Delivery · doi:10.3109/10717544.2014.880860 · Cited by 159
Aducanumab for Alzheimer’s disease?
Walsh, S., Merrick, R., Milne, R., & Brayne, C. (2021) · BMJ · doi:10.1136/bmj.n1682 · Cited by 159
Multifunctional theranostic gold nanoparticles for targeted CT imaging and photothermal therapy
Curry, T., Kopelman, R., Shilo, M., & Popovtzer, R. (2014) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1563 · Cited by 158
Huang, C.-L., Hsiao, I.-L., Lin, H.-C., Wang, C.-F., Huang, Y.-J., & Chuang, C.-Y. (2015) · Environmental Research · doi:10.1016/j.envres.2014.11.006 · Cited by 158
Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders
Vissers, C. B., Ming, G., & Song, H. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.007 · Cited by 154
Arora, S., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00461 · Cited by 149
Self-citationThe Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease
Deardorff, W. J., Feen, E. S., & Grossberg, G. T. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0273-x · Cited by 147
Cano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E. B., Galindo, R., Camins, A., García, M. L., & Turowski, P. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0443 · Cited by 144
Carradori, D., Balducci, C., Re, F., Brambilla, D., Droumaguet, B. L., Flores, O., Gaudin, A., Mura, S., Forloni, G., Ordóñez‐Gutiérrez, L., et al. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.12.006 · Cited by 143
Trends in the Molecular Pathogenesis and Clinical Therapeutics of Common Neurodegenerative Disorders
Choonara, Y. E., Pillay, V., du Toit, L. C., Modi, G., Naidoo, D., Ndesendo, V. M. K., & Sibambo, S. R. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10062510 · Cited by 134
Neurodegenerative disorders: Parkinson's disease and Huntington's disease
Hague, S., Klaffke, S., & Bandmann, O. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.060186 · Cited by 125
Nanoparticles: A Hope for the Treatment of Inflammation in CNS
Zhu, F., Hu, Y.-J., Yu, L., Zhou, X., Wu, J., Tang, Y., Qin, D., Fan, Q., & Wu, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683935 · Cited by 125
Systemic delivery to central nervous system by engineered PLGA nanoparticles.
Cai, Q., Wang, L., Deng, G., Liu, J., Chen, Q., & Chen, Z. (2016) · PubMed · Cited by 124
The role of the immune system in Alzheimer’s disease
Wu, K., Zhang, Y.-R., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101409 · Cited by 124
Spectrum of Neuropathophysiology in Spinal Muscular Atrophy Type I
Harding, B. N., Kariya, S., Monani, U. R., Chung, W. K., Benton, M., Yum, S. W., Tennekoon, G. I., & Finkel, R. S. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000144 · Cited by 122
Kim, T., Lee, N., Arifin, D. R., Shats, I., Janowski, M., Walczak, P., Hyeon, T., & Bulte, J. W. M. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201604213 · Cited by 119
Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods
Souto, E. B., Silva, G. F., Dias-Ferreira, J., Zielińska, A., Ventura, F. V., Durazzo, A., Lucarini, M., Novellino, E., & Santini, A. (2020) · Nanomaterials · doi:10.3390/nano10030455 · Cited by 119
Environmental risk factors in Parkinson's disease
Kuopio, A., Marttila, R. J., Helenius, H. Y. M., & Rinne, U. K. (1999) · Movement Disorders · Cited by 116
Arora, S., Sharma, D., & Singh, J. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00076 · Cited by 113
Self-citationRajendran, K., Anwar, A., Khan, N. A., & Siddiqui, R. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00430 · Cited by 112
Saffari, P. M., Alijanpour, S., Takzaree, N., Sahebgharani, M., Etemad‐Moghadam, S., Noorbakhsh, F., & Partoazar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117861 · Cited by 110
Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles
Baba, M., Itaka, K., Kondo, K., Yamasoba, T., & Kataoka, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.017 · Cited by 109
Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Spuch, C., Ortolano, S., & Navarro, C. (2012) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221112799219125 · Cited by 108
Cerium Oxide Nanoparticles: a ‘radical’ Approach to Neurodegenerative Disease Treatment
Naz, S., Beach, J. V., Heckert, B., Tummala, T., Pashchenko, O. I., Banerjee, T., & Santra, S. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0399 · Cited by 103
Amini, S., Saudi, A., Amirpour, N., Jahromi, M., Najafabadi, S. S., Kazemi, M., Rafienia, M., & Salehi, H. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.05.073 · Cited by 103
Disruption of blood-brain barrier in Alzheimer disease pathogenesis
Kook, S. Y., Hong, H., Moon, M., & Mook‐Jung, I. (2013) · Tissue Barriers · doi:10.4161/tisb.23993 · Cited by 101
Kempermann, G. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511499722.006 · Cited by 98
Disruption of the blood-brain barrier in parkinson's disease: curse or route to a cure?
Lee, H., & Pienaar, I. S. (2014) · Frontiers in bioscience · doi:10.2741/4206 · Cited by 96
Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases: An Overview
Morris, J. (2015) · The Neurodiagnostic Journal · doi:10.1080/21646821.2015.1075181 · Cited by 96
Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis
Wang, G., Rayner, S. L., Chung, R. S., Shi, B., & Liang, X. J. (2020) · Materials Today Bio · doi:10.1016/j.mtbio.2020.100055 · Cited by 93
Therapeutic Development in Amyotrophic Lateral Sclerosis
Bucchia, M., Ramirez, A., Parente, V., Simone, C., Nizzardo, M., Magri, F., Dametti, S., & Corti, S. P. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.12.020 · Cited by 92
Transferrin-functionalized lipid nanoparticles for curcumin brain delivery
Neves, A. R., van der Putten, L., Queiroz, J. F., Pinheiro, M., & Reis, S. (2021) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2021.03.010 · Cited by 92
Layek, B., & Singh, J. P. (2013) · Biomacromolecules · doi:10.1021/bm301720g · Cited by 91
Self-citationNew neurons in adult brain: distribution, molecular mechanisms and therapies
Pino, A., Fumagalli, G. F., Bifari, F., & Decimo, I. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.07.003 · Cited by 90
Yanagisawa, D., Amatsubo, T., Morikawa, S., Taguchi, H., Urushitani, M., Shirai, N., Hirao, K., Shiino, A., Inubushi, T., & Tooyama, I. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.03.071 · Cited by 89
Mondragón‐Rodríguez, S., Perry, G. L., Zhu, X., & Boehm, J. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/630182 · Cited by 86
Ahlschwede, K. M., Ramakrishnan, S., Poduslo, J. F., & Kandimalla, K. K. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.06.008 · Cited by 81
Pinzon-Daza, M., Campia, I., Kopecka, J., Garzon, R., Ghigo, D., & Rigant, C. (2013) · Current Drug Metabolism · doi:10.2174/1389200211314060001 · Cited by 81
Mignani, S. M., Bryszewska, M. J., Zabłocka, M., Klajnert‐Maculewicz, B., Cladera, J., Shcharbin, D., & Majoral, J. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.09.006 · Cited by 81
Efficient neuronal targeting and transfection using RVG and transferrin-conjugated liposomes
Rodrigues, B. D. S., Arora, S., Kanekiyo, T., & Singh, J. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146738 · Cited by 77
Self-citationXue, Y., Wang, N., Zeng, Z., Huang, J., Xiang, Z., & Guan, Y. (2019) · Journal of Material Science and Technology · doi:10.1016/j.jmst.2019.10.013 · Cited by 75
Bhatt, P. C., Verma, A., Al-Abbasi, F. A., Anwar, F., Kumar, V., & Panda, B. P. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s144545 · Cited by 71
Toxic effects of silver nanoparticles in mammals – does a risk of neurotoxicity exist?
Skalska, J., & Strużyńska, L. (2015) · Folia Neuropathologica · doi:10.5114/fn.2015.56543 · Cited by 62
A Role for Nanoparticles in Treating Traumatic Brain Injury
Bony, B. A., & Kievit, F. M. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090473 · Cited by 61
Dual-Modified Liposome for Targeted and Enhanced Gene Delivery into Mice Brain
Rodrigues, B. D. S., Lakkadwala, S., Kanekiyo, T., & Singh, J. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.264127 · Cited by 61
Self-citationGold Nanoparticles Mediate Improved Detection of β-amyloid Aggregates by Fluorescence
Jara-Guajardo, P., Cabrera, P., Célis, F., Soler, M., Berlanga, I., Parra‐Muñoz, N., Acosta, G., Alberício, F., Guzmán, F., Campos, M., et al. (2020) · Nanomaterials · doi:10.3390/nano10040690 · Cited by 55
Sharma, D., & Singh, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.012 · Cited by 55
Self-citationMili, B., Das, K., Kumar, A., Saxena, A. C., Singh, P., Ghosh, S., & Bag, S. (2017) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-017-6008-2 · Cited by 54
Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Merelli, A., Czornyj, L. A., & Lazarowski, A. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319380011 · Cited by 53
Liu, H., Hu, Y., Zhang, Y., Zhang, H., Gao, S., Wang, L., Wang, T., Han, Z., Sun, B.-L., & Liu, G. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00963-3 · Cited by 51
In vitro and in vivo optimization of liposomal nanoparticles based brain targeted vgf gene therapy
Arora, S., & Singh, J. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121095 · Cited by 46
Self-citationWei, M., Li, S., Yang, Z., Zheng, W., & Le, W. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0001 · Cited by 44
Lee, I., Yang, J., Lee, J. H., & Choe, Y. S. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.003 · Cited by 41
Martins, P. A. T., Alsaiari, S. K., Julfakyan, K., Nie, Z., & Khashab, N. M. (2017) · Chemical Communications · doi:10.1039/c6cc09085k · Cited by 37
Genetic Modifiers in Neurodegeneration
Jain, N., & Chen‐Plotkin, A. S. (2018) · Current Genetic Medicine Reports · doi:10.1007/s40142-018-0133-1 · Cited by 36
Nanotechnology in medicine: European research and its implications
Hofmann-Amtenbrink, M., Hofmann, H., Hool, A., & Roubert, F. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.14044 · Cited by 32
Jain, V., Baitharu, I., Barhwal, K. K., Prasad, D. N., Singh, S. B., & Ilavazhagan, G. (2012) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-012-9807-5 · Cited by 30
Zavvari, F., Nahavandi, A., & Shahbazi, A. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101799 · Cited by 29
Hinge, N. S., Kathuria, H., & Pandey, M. M. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101303 · Cited by 26
Wu, M., Lee, C.-H., & Hsiao, J. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s278687 · Cited by 18
Pathophysiology of Amyotrophic Lateral Sclerosis
Fabian, H., Clara, M., & Alvaro, G. (2013) · InTech eBooks · doi:10.5772/56562 · Cited by 17
Aliev, G. M., Daza, J., Herrera, A., Esparza, M. C. A., Morales, L., Echeverrı́a, V., Бачурин, С. О., & Barreto, G. E. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150821102631 · Cited by 15
Nanomedicinal Strategies as Emerging Therapeutic Avenues to Treat and Manage Cerebral Ischemia
Fatima, S., Quadri, S. N., Parveen, S., Beg, S., Barkat, M. A., Samim, M., Abdin, M. Z., & Ahmad, F. J. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666201102100330 · Cited by 11
Chauhan, P., Yadav, D., Koul, B., Mohanta, Y. K., & Jin, J. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666201124140518 · Cited by 11
Influencing Factors of the Pharmacokinetic Characters on Nanopharmaceutics
Ji, X., Lu, W., Wu, K., & Cho, W. (2016) · Pharmaceutical Nanotechnology · doi:10.2174/2211738505666161214142755 · Cited by 8
Smart biopolymers for controlled drug delivery applications
Arora, S., Trivedi, R., Lamptey, R. N. L., Chaulagain, B., Layek, B., & Singh, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821437-4.00005-0 · Cited by 8
Self-citation
Cited by
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Houldsworth, A. (2023) · Brain Communications · doi:10.1093/braincomms/fcad356 · Cited by 417
Gadhave, D. G., Sugandhi, V. V., Jha, S. K., Nangare, S. N., Gupta, G., Singh, S. K., Dua, K., Cho, H., Hansbro, P. M., & Paudel, K. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102357 · Cited by 358
Nimgampalle, M., Chakravarthy, H., Sharma, S., Shree, S., Bhat, A. R., Pradeepkiran, J. A., & Devanathan, V. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101994 · Cited by 207
Metadata
- Authors
- Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-02-06
- Volume
- 23
- Issue
- 3
- Pages
- 1851
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4210249097
- Cited by
- 900
- References
- 140
- FWCI
- 37.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.